Terns Pharmaceuticals, Inc. (TERN) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 Foster City, CA, 미국. 현재 CEO는 Melita Sun Jung.
TERN 을(를) 보유 IPO 날짜 2021-02-05, 59 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $4.75B.
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes TERN-101, a farnesoid X receptor agonist in Phase IIa trials for NASH; TERN-201, a vascular adhesion protein-1 inhibitor in Phase Ib development; TERN-501, a thyroid hormone receptor beta agonist in Phase I trials; and TERN-601, an oral Glucagon-Like Peptide-1 receptor agonist program targeting NASH and metabolic diseases. Founded in 2016 and headquartered in Foster City, California, Terns is advancing both single-agent and combination therapy candidates to address significant unmet medical needs in metabolic disease treatment.
